References

• 1. Aguado BA, Grim JC, Rosales AM, Watson-Capps JJ, Anseth KS. Engineering precision biomaterials for personalized medicine. Sci Transl Med 2018;10(424). google scholar
• 2. Franssen FME, Alter P, Bar N, Benedikter BJ, Iurato S, Maier D, et al. Personalized medicine for patients with COPD: Where are we? Int J COPD 2019;14:1465-84. google scholar
• 3. Gilazieva Z, Ponomarev A, Rutland C, Rizvanov A, Solovyeva V. Promising applications of tumor spheroids and organoids for per-sonalized medicine. Cancers (Basel) 2020;12(10):1-19. google scholar
• 4. Fröhlich H, Balling R, Beerenwinkel N, Kohlbacher O, Kumar S, Len-gauer T, et al. From hype to reality: Data science enabling person-alized medicine. BMC Med 2018;16(1):1-15. google scholar
• 5. Mathur S, Sutton J. Personalized medicine could transform health-care (Review). Biomed Reports 2017;7(1):3-5. google scholar
• 6. Vogenberg FR, Barash CI, Pursel M. Personalized medicine - Part 1: Evolution and development into theranostics. P T. 2010;35(10). google scholar
• 7. Papassotiropoulos A. The potential and limits of personalized medicine. 2012;1-10. google scholar
• 8. Dall’Era MA, Davies BJ, Eggener S. Active surveillance for prostate cancer. Transl Androl Urol 2018;7(2):195-6. google scholar
• 9. Sadee W, Dai Z. Pharmacogenetics/genomics and personalized medicine. Hum Mol Genet 2005;14(2):207-14. google scholar
• 10. Arciniegas Paspuel, O. G., Âlvarez Hernandez, S. R., Castro Morales, L. G., & Maldonado Gudino CW. Europe Precision Medicine Market. Graphical Research. 2021. p. 6. google scholar
• 11. Goetz LH, Schork NJ. Personalized medicine: motivation, challeng-es, and progress. Fertil Steril 2018;109(6):952-63. google scholar
• 12. Merker JD, Oxnard GR, Compton C, Diehn M, Hurley P, Lazar AJ, et al. Circulating tumor DNA analysis in patients with cancer: Ameri-can society of clinical oncology and college of American patholo-gists joint review. J Clin Oncol 2018;36(16):1631-41. google scholar
• 13. Ignatiadis M, Sledge GW, Jeffrey SS. Liquid biopsy enters the clin-ic — implementation issues and future challenges. Nat Rev Clin Oncol 2021;18(5):297-312. google scholar
• 14. Marrugo-Rarnurez J, Mir M, Samitier J. Blood-based cancer bio-markers in liquid biopsy: A promising non-invasive alternative to tissue biopsy. Int J Mol Sci 2018;19(10):1-21. google scholar
• 15. Hardingham JE. Detection of circulating tumor cells using lmmu-nobead-PCR. Clin Appl PCR 2003;2014:225-32. google scholar
• 16. Bidard FC, Fehm T, Ignatiadis M, Smerage JB, Alix-Panabieres C, Janni W, et al. Clinical application of circulating tumor cells in breast cancer: Overview of the current interventional trials. Cancer Metastasis Rev 2013;32(1-2):179-88. google scholar
• 17. Torres S, Gonzalez Â, Cunquero Tomas AJ, Calabuig Farinas S, Fer-rero M, Mirda D, et al. A profile on cobas® EGFR Mutation Test v2 as companion diagnostic for first-line treatment of patients with non-small cell lung cancer. Expert Rev Mol Diagn 2020;20(6):575-82. google scholar
• 18. Ferro M, La Civita E, Liotti A, Cennamo M, Tortora F, Buonerba C, et al. Liquid biopsy biomarkers in urine: A route towards molecular diagnosis and personalized medicine of bladder cancer. J Pers Med 2021;11(3):1-17. google scholar
• 19. Gadalla AAH, Friberg IM, Kift-Morgan A, Zhang J, Eberl M, Topley N, et al. Identification of clinical and urine biomarkers for uncom-plicated urinary tract infection using machine learning algorithms. Sci Rep 2019;9(1):1-11. google scholar
• 20. Lamb JR, Jennings LL, Gudmundsdottir V, Gudnason V, Emilsson V. It’s in Our Blood: A Glimpse of Personalized Medicine. Trends Mol Med 2021;27(1):20-30. google scholar
• 21. Schork NJ. Time for one-person trials.:3-5. google scholar
• 22. Mini E, Nobili S. Pharmacogenetics: Implementing personalized medicine. Clin Cases Miner Bone Metab 2009;6(1):17-24. google scholar
• 23. Sauna ZE, Kimchi-Sarfaty C, Ambudkar SV, Gottesman MM. Silent polymorphisms speak: How they affect pharmacogenomics and the treatment of cancer. Cancer Res 2007;67(20):9609-12. google scholar
• 24. Marsh S, Van Rooij T. Challenges of incorporating pharmacogenom-ics into clinical practice. Gastrointest Cancer Res 2009;3(5):206-7. google scholar
• 25. Ventola CL. The role of pharmacogenomic biomarkers in predict-ing and improving drug response. P T 2013;38(10):624-7. google scholar
• 26. FDA. Drugs Table of Pharmacogenomic Biomarkers in Drug Label-ing 2014;1-15. google scholar
• 27. Dere WH, Suto TS. The role of pharmacogenetics and pharmacog-enomics in improving translational medicine. Clin Cases Miner Bone Metab 2009;6(1):13-6. google scholar
• 28. John AS, P Price C. Existing and emerging technologies for point-of-care testing. Clin Biochem Rev 2014;35(3):155-67. google scholar
• 29. Nichols JH, Street C. Management of point-of-care testing. 1999;1-13. Avaible from: https://acutecaretesting.org/en/articles/man-agement-of-pointofcare-testing google scholar
• 30. Lewis K, Joyce-Nagata B, Gilmore Fite E. The Effect of time and tem-perature on blood glucose measurements. Home Healthc Nurse 1992;10(3):56-61. google scholar
• 31. Luppa PB, Müller C, Schlichtiger A, Schlebusch H. Point-of-care testing (POCT): Current techniques and future perspectives. TrAC -Trends Anal Chem 2011;30(6):887-98. google scholar
• 32. Bhardwaj V, Kapoor P, Irpachi K, Ladha S, Chowdhury U. Thailand Blood Gas Analyzer and Cardiac Biomarker Market Outlook to 2025 - Thailand’s growing number of heart disease patients with improving healthcare facilities will drive the industry growth in long term: Ken Research. Ann Card Anaesth 2017;20(1):67-71. google scholar
• 33. Çaltekin İ, Gökçen E, Albayrak L, Atik D, Savrun A, Kuşdoğan M, et al. Inflammatory markers and blood gas analysis in determining the severity of chronic obstructive pulmonary disease. Eur J Critic Care 2020;2(2):187-92. google scholar
• 34. Research K. Thailand blood gas analyzer and cardiac biomark-er market outlook to 2025 - thailand’s growing number of heart disease patients with improving healthcare facilities will drive the industry growth in long term: Ken Research. 2021; Available from: https://www.prnewswire.com/news-releases/ thailand-blood-gas-analyzer-and-cardiac-biomarker-market-outlook-to-2025---thailands-growing-number-of-heart-disease-patients-with-improving-healthcare-facilities-will-drive-the-in-dustry-growth-in-long-term-ken-res google scholar
• 35. de Oliveira Vilar Neto J, da Silva CA, Meneses GC, Pinto DV, Brito LC, da Cruz Fonseca SG, et al. Novel renal biomarkers show that cre-atine supplementation is safe: a double-blind, placebo-controlled randomized clinical trial. Toxicol Res (Camb) 2020;9(3):263-70. google scholar
• 36. Dorcely B, Katz K, Jagannathan R, Chiang SS, Oluwadare B, Gold-berg IJ, et al. Novel biomarkers for prediabetes, diabetes, and as-sociated complications. Diabetes, Metab Syndr Obes Targets Ther 2017;10: 345-61. google scholar
• 37. Memtsa M, Jurkovic D, Jauniaux ERM. Diagnostic biomarkers for predicting adverse early pregnancy outcomes: Scientific impact paper no. 58. BJOG An Int J Obstet Gynaecol 2019;126(3):e107-13. google scholar
• 38. Cho SI, Goldman MB, Ryan LM, Chen C, Damokosh AI, Christiani DC, et al. Reliability of serial urine HCG as a biomarker to detect early pregnancy loss. Hum Reprod 2002;17(4):1060-6. google scholar
• 39. Hwang H, Hwang BY, Bueno J. Biomarkers in infectious diseases. Dis Markers 2018;2018:2-3. google scholar
• 40. Zandstra J, Jongerius I, Kuijpers TW. Future biomarkers for infection and inflammation in febrile children. Front Immunol 2021;12:1-14. google scholar
• 41. Zermatten MG, Fraga M, Calderara DB, Aliotta A, Moradpour D, Al-berio L. Biomarkers of liver dysfunction correlate with a prothrom-botic and not with a prohaemorrhagic profile in patients with cir-rhosis. JHEP Reports 2020;2(4). google scholar
• 42. Nadkarni GN, Coca SG, Meisner A, Patel S, Kerr KF, Patel UD, et al. Urinalysis findings and urinary kidney injury biomarker concentra-tions. BMC Nephrol 2017;18(1):1-6. google scholar
• 43. Cirillo D, Valencia A. Big data analytics for personalized medicine. Curr Opin Biotechnol 2019;58:161-7. google scholar
• 44. Hassan M, Awan FM, Naz A, Enrique J, Alvarez O, Cernea A, et al. Innovations in genomics and big data analytics for personalized medicine and health care: A review. Int J Mol Sci 2022;23(9):4645. google scholar
• 45. Hulsen T, Jamuar SS, Moody AR, Karnes JH, Varga O, Hedensted S, et al. From big data to precision medicine. Front Med 2019;6:1-14. google scholar
• 46. Abul-Husn NS, Kenny EE. Personalized medicine and the power of electronic health records. Cell 2019;177(1):58-69. google scholar
• 47. Phillips KA, Deverka PA, Hooker GW, Douglas MP. Genetic test availability and spending: Where are we now? Where are we go-ing? Health Aff 2018;37(5):710-6. google scholar
• 48. Jacob M, Lopata AL, Dasouki M, Abdel Rahman AM. Metabolomics toward personalized medicine. Mass Spectrom Rev 2019;38(3):221-38. google scholar
• 49. Tan YJN, Yong WP, Kochhar JS, Khanolkar J, Yao X, Sun Y, et al. On-demand fully customizable drug tablets via 3D printing tech-nology for personalized medicine. J Control Release 2020;322:42-52. google scholar
• 50. Reza Soroushmehr SM, Najarian K. Transforming big data into computational models for personalized medicine and health care. Dialogues Clin Neurosci 2016;18(3):339-43. google scholar
• 51. Alrefaei AF, Hawsawi YM, Almaleki D, Alafif T, Alzahrani FA, Bakhre-bah MA. Genetic data sharing and artificial intelligence in the era of personalized medicine based on a cross-sectional analysis of the Saudi human genome program. Sci Rep 2022;12(1):1-10. google scholar
• 52. Guiot J, Vaidyanathan A, Deprez L, Zerka F, Danthine D, Frix AN, et al. A review in radiomics: Making personalized medicine a reality via routine imaging. Med Res Rev 2022;42(1):426-40. google scholar
• 53. Tamsin M. Wearable biosensor technologies. Int J Innov Sci Res 2015;13(2):697-703. google scholar
• 54. Yetisen AK, Martinez-Hurtado JL, Ünal B, Khademhosseini A, Butt H. Wearables in medicine. Adv Mater 2018;30(33):e1706910. google scholar
• 55. Dunn J, Runge R, Snyder M. Wearables and the medical revolution. Per Med 2018;15(5):429-48. google scholar
• 56. Izmailova ES, Wagner JA, Perakslis ED. Wearable devices in clinical trials: Hype and hypothesis. Clin Pharmacol Ther 2018;104(1):42-52. google scholar
• 57. Hoeben A, Joosten EAJ, van den Beuken-Van Everdingen MHJ. Per-sonalized medicine: Recent progress in cancer therapy. Cancers (Basel) 2021;13(2):1-3. google scholar
• 58. Takahashi T. Organoids for drug discovery and personalized medi-cine. Annu Rev Pharmacol Toxicol 2019;59:447-62. google scholar
• 59. Halfter K, Hoffmann O, Ditsch N, Ahne M, Arnold F, Paepke S, et al. Testing chemotherapy efficacy in HER2 negative breast cancer using patient-derived spheroids. J Transl Med 2016;14(1):1-14. google scholar
• 60. Vaz VM, Kumar L. 3D Printing as a promising tool in personalized medicine. AAPS PharmSciTech 2021;22(1):49. google scholar
• 61. Sharpton SR, Schnabl B, Knight R, Loomba R. Current concepts, opportunities, and challenges of gut microbiome-based person-alized medicine in nonalcoholic fatty liver disease. Cell Metab 2021;33(1):21-32. google scholar

Citations